Get the Stockscreener App
2.39
3.43%
-0.085
Cardiff Oncology Inc stock is traded at $2.39, with a volume of 751.54K.
It is down -3.43% in the last 24 hours and up +6.70% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$2.475
Open:
$2.49
24h Volume:
751.54K
Relative Volume:
0.93
Market Cap:
$160.99M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.5699
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
+13.27%
1M Performance:
+6.70%
6M Performance:
-36.94%
1Y Performance:
-26.91%
1-Day Range:
$2.365
$2.50
1-Week Range:
$2.11
$2.59
52-Week Range:
$1.90
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.39 | 166.72M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Zacks Small Cap Weighs in on CRDF FY2025 Earnings - Defense World
What drives Cardiff Oncology Inc stock priceSmall Cap Stock Opportunities & Free Daily Stock Hotspot Analysis - earlytimes.in
A new trading data show Cardiff Oncology Inc (CRDF) is showing positive returns. - setenews.com
Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response - Zacks Small Cap Research
Cardiff Presents Phase 1 Data Of Onvensertib In Chronic Myelomonocytic Leukemia At ASH 2025 - Nasdaq
Cardiff oncology reports positive results for onvansertib in leukemia trial - Investing.com
Cardiff oncology reports positive results for onvansertib in leukemia trial By Investing.com - Investing.com India
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 - The Manila Times
Cardiff Oncology Announces Clinical Data from - One News Page
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference - The Manila Times
Is Cardiff Oncology Inc. stock a contrarian buy2025 Key Highlights & Technical Pattern Based Signals - Newser
How Cardiff Oncology Inc. (XE7C) stock stacks up against competitorsMarket Risk Report & Low Volatility Stock Recommendations - Newser
Will Cardiff Oncology Inc. (XE7C) stock announce a stock splitAnalyst Upgrade & Technical Pattern Based Signals - Newser
Can Cardiff Oncology Inc. (XE7C) stock stage a strong rebound this quarter2025 Year in Review & High Accuracy Trade Alerts - Newser
How Cardiff Oncology Inc. (XE7C) stock reacts to stronger dollarJuly 2025 Rallies & Long-Term Investment Growth Plans - Newser
Will Cardiff Oncology Inc. stock outperform Dow Jones indexJuly 2025 Trends & Stepwise Trade Signal Guides - Newser
Cardiff Oncology (CRDF) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Cardiff Oncology Inc. stock a defensive play in 2025CPI Data & Free Daily Entry Point Trade Alerts - Newser
Is Cardiff Oncology Inc. stock attractive after correctionJuly 2025 Earnings & Real-Time Sentiment Analysis - Newser
It is Poised to be a Bull Market for Cardiff Oncology Inc (CRDF) - setenews.com
Can Cardiff Oncology Inc. stock double in next 5 yearsWall Street Watch & Fast Exit and Entry Strategy Plans - BỘ NỘI VỤ
Quarterly Trades: Will Cardiff Oncology Inc. stock benefit from green energy trendsEarnings Trend Report & Low Risk High Reward Ideas - moha.gov.vn
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.63 Average Price Target from Analysts - Defense World
AlphaCore Capital LLC Acquires Shares of 101,575 Cardiff Oncology, Inc. $CRDF - Defense World
Cardiff Oncology, Inc. to Participate in Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
Cardiff Oncology (NASDAQ: CRDF) to Join Piper Sandler 37th Conference Fireside Chat - Stock Titan
Can Cardiff Oncology Inc. (XE7C) stock hit consensus price targetsJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Cardiff Oncology Inc. forming a reversal pattern2025 Technical Patterns & Growth Focused Stock Pick Reports - newser.com
What analysts say about Cardiff Oncology Inc stockFlag and Pennant Patterns & Grow Smarter With Pro-Level Research - earlytimes.in
Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses - simplywall.st
What does recent volatility data suggest for Cardiff Oncology Inc.Market Trend Review & Fast Exit Strategy with Risk Control - newser.com
Will Cardiff Oncology Inc. (XE7C) stock beat international competitionEarnings Beat & Daily Technical Stock Forecast Reports - newser.com
Can Cardiff Oncology Inc. hit a new high this monthJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Will Cardiff Oncology Inc. stock gain from strong economyWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Using Bollinger Bands to evaluate Cardiff Oncology Inc.Entry Point & Verified Short-Term Plans - newser.com
Will Cardiff Oncology Inc. (XE7C) stock draw ESG focused fundsPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Is Cardiff Oncology Inc. stock a safe investment in uncertain marketsJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Should you hold or exit Cardiff Oncology Inc. now2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
| Levine James E. | Chief Financial Officer |
Dec 17 '24 |
Buy |
5.42 |
2,752 |
14,905 |
65,316 |
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):